1. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis
by Juliana M. F. Silva, Fani Ladomenou, Ben Carpenter, Sharat Chandra, Petr Sedlacek, Renata Formankova, Vicky Grandage, Mark Friswell, Andrew J. Cant, Zohreh Nademi, Mary A. Slatter, Andrew R. Gennery, Sophie Hambleton, Terence J. Flood, Giovanna Lucchini, Robert Chiesa, Kanchan Rao, Persis J. Amrolia, Paul Brogan, Lucy R. Wedderburn, Julie M. Glanville, Rachael Hough, Rebecca Marsh, Mario Abinun, and Paul Veys
BloodAdv
Volume 2(7):
April 10, 2018
© 2018 by The American Society of Hematology

2. Juliana M. F. Silva et al. Blood Adv 2018;2:777-786
© 2018 by The American Society of Hematology

3. Average number of affected joints pre-HSCT and at last follow-up.
Juliana M. F. Silva et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Engraftment of patients who underwent allogeneic stem cell transplantation at 3, 6, and 12 months and at the last follow-up.
Engraftment of patients who underwent allogeneic stem cell transplantation at 3, 6, and 12 months and at the last follow-up.
Juliana M. F. Silva et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Median T-cell and B-cell counts following allo-HSCT for JIA
Median T-cell and B-cell counts following allo-HSCT for JIA. Number of patients with available data at each time point.
Median T-cell and B-cell counts following allo-HSCT for JIA. Number of patients with available data at each time point.
Juliana M. F. Silva et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

6. ESR pre- and post-HSCT.
ESR pre- and post-HSCT. Data available for 15 patients pre-HSCT; for patients 1, 2, 3, 9, 11, and 16 at 3 months post-HSCT; for patients 1, 6, 9, and 11 at 6 months post-HSCT; for patients 1, 2, 8, 9, and 11 at 9 months post-HSCT, and for patients 1, 2, 6, 9, and 11 at 12 months post-HSCT.
Juliana M. F. Silva et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology